OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Rosca on Key Challenges in Genetic Testing for Lung Cancer

September 9th 2024

Oana Catalina Rosca, MD, discusses key challenges in genetic testing for lung cancer.

Dr Borczuk on Currently Offered Gene Testing for Patients With Lung Cancer

September 9th 2024

Alain Charles Borczuk, MD, discusses gene testing that may be offered for patients with lung cancer.

Dr Friedlander on Updates in Frontline Bladder Cancer Management

September 9th 2024

Terence W. Friedlander, MD, discusses updates in the frontline management of bladder cancer.

Dr Nowakowski on the Potential Benefit of Epcoritamab in Relapsed/Refractory FL

September 9th 2024

Grzegorz S. Nowakowski, MD, discusses how epcoritamab may fill an unmet need for patients with relapsed/refractory follicular lymphoma.

Dr Nowakowski on the Current Treatment Landscape for DLBCL

September 6th 2024

Grzegorz S. Nowakowski, MD, discusses the treatment landscape for DLBCL and the need for novel therapeutic approaches in the second-line setting.

Dr Seymour on the Role of Mutational Profiling in CLL

September 6th 2024

John Seymour, MBBS, FRACP, PhD, discusses the role of genetic profiling in the treatment of chronic lymphocytic leukemia.

Dr Lonial on Findings from the CoMMpass Trial in Multiple Myeloma

September 6th 2024

Sagar Lonial, MD, FACP, discusses findings from the CoMMpass trial, which identified high-risk genetic markers in patients with myeloma.

Dr Patel on the FDA Approval of Durvalumab Plus Chemotherapy for NSCLC

September 6th 2024

Sandip P. Patel, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy for patients with non–small cell lung cancer.

Dr McGregor on the Updated NCCN Guidelines for Non–Clear Cell RCC

September 6th 2024

Bradley McGregor, MD, discusses the current NCCN guideline recommendations for the treatment of patients with divergent RCC histologies.

Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCC

September 6th 2024

Moshe Ornstein, MD, MA, discusses the use of first-line IO/TKI doublet regimens in patients with non–clear cell renal cell carcinoma.

Dr Merryman on the Evolution of MRD Assays in Lymphoma

September 5th 2024

Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.

Dr Kebriaei on the Potential Shift Away From Transplant in ALL

September 5th 2024

Partow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.

Dr Lee on Treatment Considerations for Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

September 5th 2024

John K. Lee, MD, PhD, discusses treatment considerations for the use of enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer.

Dr Koff on the Role of Covalent BTK Inhibitors and Pirtobrutinib in MCL

September 5th 2024

Jean L. Koff, MD, MS, discusses the role of covalent BTK inhibitors in the treatment of mantle cell lymphoma.

Dr Nagpal on the FDA Approval of Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma

September 5th 2024

Seema Nagpal, MD, discusses the FDA approval of vorasidenib for patients with astrocytoma or oligodendroglioma harboring IDH1 or IDH2 mutations.

Dr Cooper on Considerations to Help Guide ADC Use in Second-Line NSCLC

September 5th 2024

Alissa J. Cooper, MD, discusses insights from the TROPION-Lung01 trial that may help guide antibody-drug conjugate use in second-line NSCLC.

Dr Smith on Bispecific Antibodies for the Management of R/R Follicular Lymphoma

September 4th 2024

Sonali M. Smith, MD, discusses the current arsenal of bispecific antibodies available for the management of relapsed/refractory follicular lymphoma.

Dr Giralt on Determining Transplant Eligibility in MDS

September 4th 2024

Sergio A. Giralt, MD, discusses how to determine transplant eligibility and the evolving role of transplant for patients with myelodysplastic syndromes.

Dr Grunwald on the Patient Population and Limitations of the REVEAL Study in PV

September 4th 2024

Michael R. Grunwald, MD, FACP, discusses the characteristics of patients with polycythemia vera enrolled in the REVEAL study and limitations of the study.

Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular Lymphoma

September 4th 2024

Grzegorz S. Nowakowski, MD, discusses results from the EPCORE NHL-1 trial of third-line epcoritamab in relapsed/refractory follicular lymphoma.